Free Republic 4th Qtr 2022 Fundraising Target: $80,000 Receipts & Pledges to-date: $1,637
Woo hoo!! And our first 2% is in!! Thank you all very much!! God bless.

Keyword: merck

Brevity: Headers | « Text »
  • Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill

    01/07/2022 3:46:33 PM PST · by entropy12 · 23 replies
    Reuters ^ | January 4, 2022 | Reuters
    BENGALURU, Jan 4 (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd (REDY.NS) will launch its generic version of Merck's (MRK.N) antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday. The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to 1,400 rupees ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700.
  • India Won’t Add Merck’s COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns

    01/06/2022 9:22:01 AM PST · by SeekAndFind · 4 replies
    Epoch Times ^ | 01/06/2022 | Katabella Roberts
    India’s top health research body announced on Wednesday that it won’t be adding Merck’s COVID-19 antiviral pill molnupiravir to its national treatment protocol, citing concerns over its safety.The state-run Indian Council of Medical Research (ICMR) said it had become aware of “major safety concerns” that prompted the decision, despite India’s drug regulator in December approving the drug for emergency use.It comes after France in December also canceled its order for the drug, developed by Merck and Ridgeback Biotherapeutics, following disappointing trial data suggesting its drug was markedly less effective than previously thought.“Molnupiravir has major safety concerns including teratogenicity, mutagenicity, muscle...
  • CDC Pressed to Acknowledge Industry Funding

    11/04/2021 5:08:13 PM PDT · by CheshireTheCat · 12 replies
    Ash Clinical News ^ | NOVEMBER 18, 2019 | Staff
    A petition from advocacy groups is calling for the Centers for Disease Control and Prevention (CDC) to stop claiming it does not have relationships with or accept financial support from drug manufacturers and other companies that might benefit from agency research. The CDC has accepted millions of dollars through the CDC Foundation, according to the groups behind the petition. During fiscal years 2014 through 2018, the CDC Foundation received $79.6 million from companies like Pfizer, Biogen, and Merck. Since it was created by Congress in 1995, the nonprofit organization has accepted $161 million from corporations. Public Citizen, Knowledge Ecology International,...
  • Merck’s New Covid Pill Is a Disaster

    12/17/2021 8:01:05 PM PST · by E. Pluribus Unum · 17 replies
    Freedom First Network ^ | December 17, 2021 | Dr. Joseph Mercola
    STORY AT-A-GLANCEAn advisory panel to the U.S. Food and Drug Administration voted to grant emergency authorization to Merck’s oral COVID-19 pill molnupiravir (Lagevrio) — by a narrow 13-to-10 marginAmong those who received the drug, the rate of all-cause hospitalization or death was 6.8%, compared to 9.7% in the placebo group — a relative risk reduction of just 30%The full data showed more hospital admissions among patients taking molnupiravir (6.2%) than among those taking a placebo (4.7%)Molnupiravir works by triggering mutations that ultimately kill the virus; a risk of cancer and birth defects is possible, and the drug shouldn’t be taken...
  • “Supply Issues” Pause UK Ivermectin Trial as Merck Lands $2.2B US Govt. Contract for New Drug

    12/16/2021 6:25:40 PM PST · by bitt · 19 replies ^ | 12/16/2021 | Michelle Edwards
    In late June, the University of Oxford announced that PRINCIPLE, one of the U.K. Government’s national priority platform trials of COVID-19 treatments, would be evaluating Ivermectin, the seventh treatment to be investigated in the PRINCIPLE trial. Along with the influenza antiviral drug favipiravir, Ivermectin, the “safe, broad-spectrum antiparasitic drug,” was added as part of the trial’s focus on treatment for people in the U.K. who have recently developed symptoms of COVID-19. Yet, suddenly, without an explanation from Merck—who is a key manufacturer of the generic, readily available drug Ivermectin—MedPage Today reports that PRINCIPLE’s trial on the drug is paused, stating:...
  • NYT Admits Merck’s Covid Drug Could Mutate DNA, Cause Cancer & Damage Male Fertility...Bombshell admission buried near the bottom of the article

    12/14/2021 12:47:03 PM PST · by Red Badger · 65 replies ^ | December 14th 2021, 1:35 pm | by Kelen McBreen
    An alarming admission was found near the bottom of a recent New York Times article about pharmaceutical giant Merck’s new Covid drug molnupiravir. Approved by the FDA two weeks ago, the drug was studied on isolated hamster cells for 32 days before being given the green light. While the FDA narrowly voted to recommend emergency use authorization for the drug, France’s National Authority of Health on Friday cited the pill’s own lack of efficacy as it ruled it will not be used in the European nation. According to the NYT report, “A team of researchers at the University of North...
  • Merck’s COVID-19 Pill Molnupiravir May Be Less Effective Than First Hoped

    11/30/2021 3:29:32 PM PST · by SeekAndFind · 16 replies
    WebMD ^ | 11/30/2021 | Brenda Goodman, MA
    Merck’s antiviral pill for COVID-19, molnupiravir, appears to be far less effective than early results from the clinical trial first suggested.According to an analysis by scientists at the FDA, the experimental pill cut the risk of hospitalization or death from COVID-19 by about 30%, compared to a placebo, and the pill showed no benefit for people with antibodies against COVID-19 from prior infection.The updated analysis showed 48 hospitalizations or deaths among study participants who were randomly assigned to take the antiviral drug, compared to 68 among those who took a placebo.Those results come from the full set of 1,433 patients...
  • Merck says COVID-19 pill may not be as effective as they thought

    11/26/2021 12:13:44 PM PST · by ChicagoConservative27 · 25 replies
    Nypost ^ | 11/26/2021 | Selim Algar
    Pharmaceutical giant Merck said Friday that its COVID-19 pill could be less effective than originally thought. The drugmaker said the experimental pill, molnupiravir, was shown to be 30 percent effective in fighting hospitalizations and deaths in a study of 1,433 patients.
  • Biden administration to announce purchase of 10 million courses of Pfizer anti-covid pill - Paxlovid: Officials see the treatment, and another by Merck, as potential game-changers to help tame the pandemic

    11/16/2021 12:28:19 PM PST · by SeekAndFind · 31 replies
    Washington Post ^ | 11/16/2021 | Tyler Pager and Laurie McGinley
    The Biden administration is expected to announce this week that it is purchasing 10 million courses of Pfizer’s covid pill, a multibillion-dollar investment in medication that officials hope will help change the trajectory of the pandemic by staving off many hospitalizations and deaths, according to two people with knowledge of the transaction. U.S. officials see this antiviral pill, and another by Merck and Ridgeback Biotherapeutics, as potential game-changers to help restore a broader sense of normalcy and are eager to add them to a small arsenal of treatments for Americans who contract the coronavirus. With breakthrough cases rising and 30...
  • Britain Becomes First Country to Approve Merck’s Oral COVID-19 Antiviral Drug, Molnupiravir

    11/04/2021 8:29:52 PM PDT · by SeekAndFind · 4 replies
    US News and World Report ^ | 11/04/2021 | Kaia Hubbard
    Britain authorized the world’s first antiviral pill to treat the coronavirus, which may cut the risk of hospitalization and death from COVID-19 in half among the unvaccinated. Britain on Thursday granted conditional authorization to drugmaker Merck's COVID-19 antiviral pill, becoming the first country in the world to OK the virus treatment. The drug, developed by U.S.-based Merck and Ridgeback Biotherapeutics, is the first pill to gain regulatory approval to treat the coronavirus, aimed at alleviating mild-to-moderate COVID-19 in at-risk adults. It's intended to be taken twice per day for five days. The authorization comes after the drug garnered positive results...
  • UK conditionally authorizes Merck COVID-19 pill

    11/04/2021 6:10:28 AM PDT · by ChicagoConservative27 · 12 replies
    The Hill ^ | 11/04/2021 | CAROLINE VAKIL
    Merck announced on Thursday that the United Kingdom conditionally authorized the use of its antiviral COVID-19 pill, molnupiravir. The pharmaceutical company said that molnupiravir, developed with Ridgeback Biotherapeutics, had been authorized for use in Britain to treat mild to moderate cases of COVID-19 for adults with positive COVID-19 tests who had “at least one risk factor for developing severe illness.” The conditional authorization was based on an analysis of phase-three trials that found that use of the antiviral COVID-19 pill drastically reduced hospitalization in people who were administered molnupiravir.
  • UK authorizes Merck antiviral pill, 1st shown to treat COVID

    11/04/2021 4:21:55 AM PDT · by Eleutheria5 · 18 replies
    Yahoo! News ^ | 4/11/21 | Matthew Perone & Maria Cheng
    LONDON (AP) — Britain has granted a conditional authorization to Merck's coronavirus antiviral, the first pill shown to successfully treat COVID-19. It is the first country to OK the treatment, although it was not immediately clear how quickly the pill would be available. The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease. The drug, known as molnupiravir, is intended to be taken twice a day for five days by people at home with mild to moderate COVID-19....
  • HPV vaccine is making cervical cancer a 'thing of the past': Jabs prevent up to 90% of cases of the disease, major study finds

    11/03/2021 6:25:55 PM PDT · by algore · 26 replies
    Cervical cancer has been virtually eradicated in young women because of the HPV vaccine's 'remarkable' success, a major study has found. Cases of the disease have plummeted by 87 per cent as a result of the NHS vaccine programme. Among women now in their twenties — the first generation to get the jab — cases have now dropped from about 50 per year to just five. Today's 'historic' findings by King's College London represent the first evidence the HPV vaccine is saving lives in the UK. The HPV vaccine prevents infection from human papillomavirus, a common group of viruses that...
  • Ivermectin vs. Merck’s New Antiviral, Molnupiravir: How Do They Stack Up Against Covid?

    10/25/2021 10:19:24 PM PDT · by SeekAndFind · 7 replies
    BASED ^ | 10/25/2021 | JD Rucker
    Editor’s Commentary: Before we get to Dr. Joseph Mercola’s article below, I thought I would offer my two conspiratorial cents on what’s driving Molnupiravir to be released instead of Ivermectin against Covid-19. First and foremost, I do not believe it is as effective as Ivermectin, and that’s the point. They don’t want an effective treatment to hamper their universal vaccination agenda, so by approving Molnupiravir instead of Ivermectin, they’re maintaining their push.This is not based on any science as I know nothing about the composition of either drug. The science is discussed below by smarter people than me. My theory...
  • Why Merck Dissed Its Own Invention Ivermectin Against Covid-19

    10/13/2021 9:09:44 PM PDT · by SeekAndFind · 16 replies
    Science Matters ^ | 10/13/2021 | Ron Clutz
    Reuters reports October 1, 2021 Merck pill seen as ‘a huge advance’, raises hope of preventing COVID-19 deaths. Excerpts in italics with my bolds.Co will seek U.S. approval for pill as soon as possibleIf approved, would be 1st oral antiviral COVID-19 drugMerck shares rally, some vaccine makers fallU.S govt agreed to buy 1.7 mln courses at $700 eachAn antiviral pill developed by U.S. drugmaker Merck & Co (MRK.N) could half the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, with experts hailing it as a potential breakthrough in how the virus is treated.If...
  • Fact Check - Merck’s experimental COVID-19 antiviral drug is not ‘repackaged Ivermectin’

    10/13/2021 7:49:06 AM PDT · by SeekAndFind · 42 replies
    Reuters ^ | 10/13/2021 | Reuters Fact Check
    Some social media users have been saying that Merck’s experimental COVID-19 antiviral product molnupiravir is a rebranded version of the anti-parasitic Ivermectin. Two disease experts have told Reuters that this is not the case and that the chemical make-up of the two drugs is different. One tweet (here ) reads, “Ivermectin is a safe cure that was removed from CDC treatment protocol. Merck refurbishes it and *poof, it’s a miracle pill. Further proof that Big Pharma is in the business of creating customers.” Similar posts on Facebook are visible here and here .One reads, in part, “The pharmaceutical giant Merck...
  • Merck Asks FDA For Emergency Use Authorization For Its $700 COVID Pill, Biden Already Bought 1.7 Million

    10/12/2021 11:36:52 AM PDT · by Red Badger · 26 replies ^ | TOM PAPPERT October 12, 2021
    Biden spends over $2.4 billion on Merck wonder drug so good it deserves a 4,000% markup =========================================================================== Yesterday the pharmaceutical giant Merck asked the Food and Drug Administration to grant emergency use authorization for its new pill, Malnupiravir, that can treat COVID-19 for the eye watering price of $712, and Joe Biden already bought 1.7 million. The drug costs Merck $17.74 to produce. “Merck said it is asking for authorization for the capsules to treat infected adults who are at risk of progressing to severe Covid-19 disease or hospitalization,” reported CNN. A drug trial for Malnupiravir was reportedly ended early...
  • Merck seeks FDA emergency use authorization for antiviral Covid-19 treatment molnupiravir

    10/11/2021 8:09:45 AM PDT · by American Number 181269513 · 48 replies
    CNN ^ | October 11, 2021 | Jamie Gumbrecht and Maggie Fox
    Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.If authorization is granted, the drug, made by Merck and Ridgeback Biotherapeutics, would be the first oral antiviral treatment to fight Covid-19. It comes in capsule form. Merck said it is asking for authorization for the capsules to treat infected adults who are at risk of progressing to severe Covid-19 disease or hospitalization. Its submission is based on a study that was stopped at the interim point because the drug was working so well in more than 700 patients randomly...
  • Report, 100 to 200 Congressional Reps and Staff Were Treated with Ivermectin Protocol From Front Line COVID Critical Care Doctors

    10/10/2021 7:56:46 AM PDT · by george76 · 58 replies
    The Conservative Treehouse ^ | October 9, 2021 | Sundance
    This is beyond disturbing. According to Dr Pierre Kory, MD, MPA, and verified by the Front Line COVID-19 Critical Care Alliance (FLCCC), 100 to 200 congressional reps and/or staff and families who contracted COVID-19 were treated with the Front Line Ivermectin protocol. ... This successful treatment is happening at the same time many congressional representatives are playing politics in favor of the vaccine; downplaying the effective anti-viral treatment and therapeutic approach with Ivermectin; and taking action to block regular American citizens from seeking similar treatment with Ivermectin. Congress can seek treatment with a medication they simultaneously deny to others? This...
  • Merck’s 4,000% Markup of Taxpayer-Funded COVID Drug Is ‘Extortion,’ Critics Say

    10/08/2021 9:37:05 PM PDT · by bitt · 35 replies ^ | 10/7/2021 | jake johnson
    Pharma giant Merck is facing accusations of price gouging after it charged the U.S. more than $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce. he New Jersey-based pharmaceutical giant Merck is facing accusations of price gouging after it charged the U.S. over $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce. Last week, Merck announced plans to request emergency federal authorization for molnupiravir after a late-stage clinical trial showed that a five-day course of the antiviral drug cut the risk of COVID-19 hospitalization...